Chromosome 7 gain compensates for chromosome 10 loss in glioma.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
30 Jul 2024
Historique:
accepted: 25 07 2024
received: 24 04 2024
revised: 23 07 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: aheadofprint

Résumé

The co-occurrence of chromosome 10 loss and chromosome 7 gain in gliomas is the most frequent loss-gain co-aneuploidy pair in human cancers. This phenomenon has been investigated since the late 1980s without resolution. Expanding beyond previous gene-centric studies, we investigated the co-occurrence in a genome-wide manner taking an evolutionary perspective. Mining of large-scale tumor aneuploidy data confirmed the previous finding of a small-scale longitudinal study that the most likely order is chromosome 10 loss followed by chromosome 7 gain. Extensive analysis of genomic and transcriptomic data from both patients and cell lines revealed that this co-occurrence can be explained by functional rescue interactions that are highly enriched on chromosome 7, which could potentially compensate for any detrimental consequences arising from the loss of chromosome 10. Transcriptomic data from various normal, non-cancerous human brain tissues were analyzed to assess which tissues may be most predisposed to tolerate compensation of chromosome 10 loss by chromosome 7 gain. The analysis indicated that the pre-existing transcriptomic states in the cortex and frontal cortex, where gliomas arise, are more favorable than other brain regions for compensation by rescuer genes that are active on chromosome 7. Collectively, these findings suggest that the phenomenon of chromosome 10 loss and chromosome 7 gain in gliomas is orchestrated by a complex interaction of many genes residing within these two chromosomes and provide a plausible reason why this co-occurrence happens preferentially in cancers originating in certain regions of the brain.

Identifiants

pubmed: 39078448
pii: 746734
doi: 10.1158/0008-5472.CAN-24-1366
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Nishanth Ulhas Nair (NU)

National Institutes of Health, Bethesda, Maryland, United States.

Alejandro A Schaffer (AA)

National Cancer Institute, Bethesda, Maryland, United States.

E Michael Gertz (EM)

NCI/NIH, Bethesda, MD, United States.

Kuoyuan Cheng (K)

National Cancer Institute, Bethesda, MD, United States.

Johanna Zerbib (J)

Tel Aviv University, Tel Aviv, Israel.

Avinash Das Sahu (AD)

University of New Mexico, United States.

Gil Leor (G)

Tel Aviv University, Tel Aviv, Israel.

Eldad D Shulman (ED)

National Cancer Institute, Bethesda, United States.

Kenneth D Aldape (KD)

National Cancer Institute, Bethesda, Maryland, United States.

Uri Ben-David (U)

Tel Aviv University, Tel Aviv, Israel.

Eytan Ruppin (E)

National Cancer Institute, Bethesda, MD, United States.

Classifications MeSH